Bioventus (BVS) Liabilities and Shareholders Equity (2020 - 2026)

Bioventus (BVS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $650.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 5.91% year-over-year to $650.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (down 8.0% YoY) and the FY2025 annual result came in at $683.6 million, down 6.1% from the prior year.
• Liabilities and Shareholders Equity retreated to $650.5 million in Q1 2026, from $683.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q4 2022 to a low of $650.5 million in Q1 2026.
• A 5-year average of $884.7 million and a median of $794.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 113.51% — and 2023, when it tumbled 41.98%.
• Tracing BVS's Liabilities and Shareholders Equity over 5 years: stood at $1.4 billion in 2022, then plunged by 40.92% to $810.9 million in 2023, then fell by 10.23% to $728.0 million in 2024, then dropped by 6.1% to $683.6 million in 2025, then declined by 4.83% to $650.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $650.5 million (Q1 2026), $683.6 million (Q4 2025), and $701.6 million (Q3 2025), per Business Quant data.